Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07680829 Icosapent Ethyl Hypertriglyceridemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07680829, evaluating Icosapent Ethyl in Hypertriglyceridemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07701993 Efimosfermin alfa MASH Cirrhosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07701993, evaluating Efimosfermin alfa in MASH Cirrhosis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07596329 Furosemide Cardiorenal Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07596329, evaluating Furosemide in Cardiorenal Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07635914 Aprocitentan Resistant Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07635914, evaluating Aprocitentan in Resistant Hypertension: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07693777 DR-10624 Hypertriglyceridemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07693777, evaluating DR-10624 in Hypertriglyceridemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07428538 Larsucosterol Alcohol-Associated Hepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07428538, evaluating Larsucosterol in Alcohol-Associated Hepatitis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
ChiCTR2600125945 Sunvozertinib KRAS G12C NSCLC Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into ChiCTR2600125945, evaluating Sunvozertinib in KRAS G12C NSCLC: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07695948 Triple-Negative Breast Cancer Triple-Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07695948, evaluating Triple-Negative Breast Cancer in Triple-Negative Breast Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07686588 Sacituzumab tirumotecan Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07686588, evaluating Sacituzumab tirumotecan in Head and Neck Squamous Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
ChiCTR2600128212 Almonertinib Mesilate EGFR-Mutant NSCLC Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into ChiCTR2600128212, evaluating Almonertinib Mesilate in EGFR-Mutant NSCLC: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07689201 Velzatinib Gastrointestinal Stromal Tumors Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07689201, evaluating Velzatinib in Gastrointestinal Stromal Tumors: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07602946 Navlimetostat Mesothelioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07602946, evaluating Navlimetostat in Mesothelioma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.